Osteoprotegerin, rank ve rank ligand
Yıl: 2007 Cilt: 32 Sayı: 4 Sayfa Aralığı: 178 - 184 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Osteoprotegerin, rank ve rank ligand
Öz: Osteoprotegerin, reseptör aktivatör nükleer kappa B ve reseptör aktivatör nükleer kappa B ligand’ın keşfi ve osteoklastojenezisteki rollerinin belirlenmesi kemik biyolojisinin anlaşılmasına çok önemli katkılar sağlamıştır. Reseptör aktivatör nükleer kappa B ligand preosteoklastların üzerindeki reseptörü reseptör aktivatör nükleer kappa B’e bağlanarak, onların osteoklastlara dönüşmesini uyarır ve böylece kemik rezorpsiyonu oluşur. Osteoprotegerin ise reseptör aktivatör nükleer kappa B ligand için yalancı reseptör görevi görür ve kemik rezorpsiyonunu inhibe eder. Kemik biyolojisinin anlaşılmasına sağladıkları bu temel bakış açısı dışında osteoprotegerin, reseptör aktivatör nükleer kappa B ve reseptör aktivatör nükleer kappa B ligand’ın immün sistem, arteryel kalsifikasyon ve pek çok metabolik kemik hastalığı ile de ilgili olabilecekleri belirtilmiştir. Bu derlemede osteoprotegerin, reseptör aktivatör nükleer kappa B ve reseptör aktivatör nükleer kappa B ligand’ın kemik rezorpsiyonu, immün sistem ve arteryel kalsifikasyondaki rolünün ve tedavideki yerinin özetlenmesi amaçlanmıştır.
Anahtar Kelime: Konular:
Osteoprotegerin, rank and rank ligand
Öz: The discovery of the osteoprotegerin, receptor activator of nuclear factor-kappa B ligand and receptor activator of nuclear factor-kappa B and identification of their role in osteoclastogenesis provided a major advance in bone biology. receptor activator of nuclear factor-kappa B ligand binds to its receptors on the surface of preosteoclasts and stimulates their differentiation into active osteoclasts, leading to bone resorption. Osteoprotegerin is a soluble decoy receptor for the receptor activator of nuclear factor-kappa B ligand thereby inhibiting bone resorption. In addition to providing fundamental insights in bone biology, they may be involved in the immune system, arterial calcification and a number of metabolic bone diseases. In this review, we summarize the roles of receptor activator of nuclear factor-kappa B, receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in bone metabolism, immune system and arterial calcification and discuss their potential in the treatment of these diseases. Key Words: Osteoprotegerin, receptor activator of nuclear factor-kappa B, receptor activator of nuclear factor-kappa B ligand, Bone resorption, Immune system,
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- [1] Kostenuik PJ, Shalhoub V. (2001) Osteoprotegerin: A Physiological and Pharmacological Inhibitor of Bone Resorption. Curr Pharm Des. 7: 613-35. [2] Boyce BF, Xing L. (2007) Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 9:1. [3] Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davey E, Bucay N, Renshaw- Gregg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ. (1997) Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309–319. [4] Tsuda E, Goto M, Mochizuki SI, Yano K, Kobayashi F, Morinaga T, Higashio K. (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 234: 137–42. [5] Lacey DL, Timms E, Tan H-L, Kelly MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy F, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalboub V, Senaldi G, Guo J, Delaney J, Boyle WJ. (1998) Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93: 165–176. [6] Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95: 3597–602. [7] Hofbauer LC. (1999) Osteoprotegerin ligand and osteoprotegerin: Novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol 141: 195–210. [8] Blair JM, Zheng Y, Dunstan CR. (2007) RANK ligand. Int J Biochem Cell Biol. 39: 1077-81. [9] Khosla S. (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology. 142: 5050-5. [10] Schoppet M, Preissner KT, Hofbauer LC. (2002) RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 22: 549-53. [11] Stejskal D, Bartek J, Pastorkova R, Ruzicka V, Oral I, Horalik D. (2001) Osteoprotegerin, RANK, RANKL. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 145: 61-4. [12] Hofbauer LC, Neubauer A, Heufelder AE. (2001) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer. 92: 460-70. [13] Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S. (2002) Osteoprotegerin deficiency and juvenile Paget’s disease. N Engl J Med. 347: 175-84. [14] Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J. (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet .11: 2119-27. [15] Brandstrom H, Bjorkmann T, Ljunggren O. (2001) Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun. 280: 831–35. [16] Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, McClure D, Seno G, Churgay L, Chandrasekhar S, Martin TJ. (2000) In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res. 15 :863–71. [17] Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S. (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 140: 4382–9. [18] Boyce BF, Xing L, Chen D. (2005) Osteoprotegerin, the bone protector, is a surprising target for beta-catenin signaling. Cell Metab. 2: 344-5. [19] Makhluf HA, Mueller SM, Mizuno S, Glowacki J. (2000) Agerelated decline in osteoprotegerin expression by human bone marrow cells cultured inthree-dimensional collagen sponges. Biochem Biophys Res Commun. 268: 669–7. [20] Kobayashi Y, Hashimoto F, Miyamoto H, Kanaoa K, Miyazaki-Kawashita Y, Nakashima T, Shibata M, Kobayashi K, Kato Y, Sakai H. (2000) Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor- and osteoprotegerin expression. J Bone Miner Res. 15: 1924–34. [21] Szalay F, Hegedus D, Lakatos PL, Tornai I, Bajnok E, Dunkel K, Lakatos P. (2003) High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol. 38: 395-400. [22] Kurban S, Akpinar Z, Mehmetoglu I. (2007) Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin levels in multiple sclerosis Multiple Sclerosis. (yayın aşamasında). [23] Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKLRANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 12: 17-25. [24] Takayanagi H. (2005) Inflammatory bone destruction and osteoimmunology. J Periodont Res. 40: 287–93. [25] Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T. (2002) RANKL maintains bone homeostasis through c-Fosdependent induction of interferon-beta. Nature. 416: 744-9. [26] Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM. (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 103: 41–50. [27] Kim NS, Kim HJ, Koo BK, Kwon MC, Kim YW, Cho Y, Yokota Y, Penninger JM, Kong YY. (2006) Receptor activator of NFkappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol. 26: 1002-13. [28] Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM. (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 440: 692–6. [29] Kim HH, Shin HS, Kwak HJ, Ahn KY, Kim JH, Lee HJ, Lee MS, Lee ZH, Koh GY. (2003) RANKL regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway, FASEB J. 17: 2163–5. [30] Anderson MA, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390: 175–9. [31] Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 96: 3540–3545 [32] Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. (2006) Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 107: 289-98. [33] Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, Mc-Cabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ. (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97: 156-71. [34] Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM. (2000) Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis, Nat Genet. 24: 45–8. [35] Feng X. (2005) RANKing intracellular signaling in osteoclasts. IUBMB Life. 57: 389-95. [36] Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett 3rd FS, Frankel WN, Lee SY, Cho Y. (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun Nterminal kinase in T cells. J Biol Chem. 272: 25190–4. [37] Wong BR, Josien R, Young Lee S, Vologodskaia M, Steinman RM & Choi Y. (1998) The TRAF family of signal transducers mediates NF-kB activation by the TRANCE receptor. J Biol Chem. 273: 28355–9. [38] Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall-WC. (1998) The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanism of receptor activator of NF-kB, a member of the TNFR superfamily. J Biol Chem. 273: 34120–7. [39] Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW. (1999) TRAF6 deficiency results in osteopetrosis and defective nterleukin-1, CD40, and LPS signaling. Genes Dev. 13: 1015-24. [40] Wada T, Nakashima T, Oliveira-dos-Santos AJ, Gasser J, Hara H, Schett G, Penninger JM. (2005) The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat Med. 11: 394-9. [41] Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M, Steinman RM, Choi Y. (2000) TRANCE, a TNF family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med. 191: 495–502. [42] Wong BR, Josien R, Choi Y. (1999) TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol. 65: 715–24. [43] Schoppet M, Henser S, Ruppert V, Stübig T, Al-Fakhri N, Maisch B, Hofbauer LC. (2007) Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent J Cell Biochem. 100: 1430-9. [44] Kong Y-Y, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397: 315–23. [45] Yun TJ, Tallquist MD, Aicher A, Rafferty KL, Marshall AJ, Moon JJ, Ewings ME, Mohaupt M, Herring SW, Clark EA. (2001) Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol. 166: 1482–91. [46] Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. (2000) Osteoprotegerin is an alpha vbeta 3-induced, NF-κB-dependent survival factor for endothelial cells. J Biol Chem 275: 20959–62. [47] Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O’Brien T, Khosla S. (2001) Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary smooth muscle cells. Biochem Biophys Res Commun. 280: 334–9. [48] Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H. (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 247: 610–5. [49] Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC. (2000) Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol. 20: 1926–31. [50] Kado DM, Browner WS, Blackwell T, Gore R, Cummings SR. (2000) Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res. 15: 1974-80. [51] Browner WS, Lui LY, Cummings SR. (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 86: 631–7. [52] Price PA, June HH, Buckley JR, Williamson MK. (2001) Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 21: 1610–6. [53] Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 192: 463–74. [54] Price PA, Faus SA, Williamson MK. (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 21: 817–824. [55] Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 140: 4367–70. [56] Yano K, Tsuda N, Kobayashi F, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y. (1999) Immunological Characterization of Circulating Osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res. 14: 518–27. [57] Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 16: 348-60. [58] Honore P, Luger NM, Sabino MC, Schwei MJ, Rogers SD, Mach DB,O’Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW. (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med. 6: 521–8. [59] Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. (2001) Therapeutic efficacy of a soluble receptor activator of nuclear factor κB IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 61: 2572–8. [60] Dunstan CR. (2000) Osteoprotegerin and osteoprotegerin ligand mediate the local regulation of bone resorption. Endocrinologist. 10: 18–21. [61] Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM. (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women, J Bone Miner Res. 19: 1059-66. [62] Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ. (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer, Clin Cancer Res. 12: 1221–8.
| APA | Kurban S, MEHMETOĞLU İ (2007). Osteoprotegerin, rank ve rank ligand. , 178 - 184. |
| Chicago | Kurban Sevil,MEHMETOĞLU İdris Osteoprotegerin, rank ve rank ligand. (2007): 178 - 184. |
| MLA | Kurban Sevil,MEHMETOĞLU İdris Osteoprotegerin, rank ve rank ligand. , 2007, ss.178 - 184. |
| AMA | Kurban S,MEHMETOĞLU İ Osteoprotegerin, rank ve rank ligand. . 2007; 178 - 184. |
| Vancouver | Kurban S,MEHMETOĞLU İ Osteoprotegerin, rank ve rank ligand. . 2007; 178 - 184. |
| IEEE | Kurban S,MEHMETOĞLU İ "Osteoprotegerin, rank ve rank ligand." , ss.178 - 184, 2007. |
| ISNAD | Kurban, Sevil - MEHMETOĞLU, İdris. "Osteoprotegerin, rank ve rank ligand". (2007), 178-184. |
| APA | Kurban S, MEHMETOĞLU İ (2007). Osteoprotegerin, rank ve rank ligand. Türk Biyokimya Dergisi, 32(4), 178 - 184. |
| Chicago | Kurban Sevil,MEHMETOĞLU İdris Osteoprotegerin, rank ve rank ligand. Türk Biyokimya Dergisi 32, no.4 (2007): 178 - 184. |
| MLA | Kurban Sevil,MEHMETOĞLU İdris Osteoprotegerin, rank ve rank ligand. Türk Biyokimya Dergisi, vol.32, no.4, 2007, ss.178 - 184. |
| AMA | Kurban S,MEHMETOĞLU İ Osteoprotegerin, rank ve rank ligand. Türk Biyokimya Dergisi. 2007; 32(4): 178 - 184. |
| Vancouver | Kurban S,MEHMETOĞLU İ Osteoprotegerin, rank ve rank ligand. Türk Biyokimya Dergisi. 2007; 32(4): 178 - 184. |
| IEEE | Kurban S,MEHMETOĞLU İ "Osteoprotegerin, rank ve rank ligand." Türk Biyokimya Dergisi, 32, ss.178 - 184, 2007. |
| ISNAD | Kurban, Sevil - MEHMETOĞLU, İdris. "Osteoprotegerin, rank ve rank ligand". Türk Biyokimya Dergisi 32/4 (2007), 178-184. |
